Abstract
Our study illustrated that EMPA might directly interact with FZD4 to inhibit the TAC and AngII-induced activation of the Wnt/β-catenin pathway to attenuate the adverse cardiac remodeling.
Introduction
Cardiac hypertrophy, the thickening of the heart muscle in response to chronic pressure overload (such as hypertension), is a precursor to heart failure, arrhythmias, and sudden cardiac death. While initially a compensatory mechanism, prolonged hypertrophy leads to pathological remodeling and functional decline.
Empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated significant cardiovascular benefits in clinical trials like EMPEROR-Reduced, even in patients without diabetes. However, because SGLT2 expression is minimal in the heart, the direct molecular mechanisms of its cardioprotective effects remain poorly understood. This study investigates whether EMPA directly targets the canonical Wnt/β-catenin signaling pathway, a known driver of pathological cardiac remodeling.
Methods
The researchers utilized a multi-scale experimental approach:
- In Vivo Models: Transverse Aortic Constriction (TAC) was performed on C57BL/6J mice to simulate pressure overload. Mice were treated with EMPA (10 mg/kg/day) for 8 weeks.
- Genetic Validation: Transgenic mice with cardiomyocyte-specific deletion of β-catenin (β-catenin flox/+, αMHC-Cre+) were used to confirm the pathway's involvement.
- In Vitro Analysis: Neonatal Rat Cardiomyocytes (NRCMs) and Adult Mouse Cardiomyocytes (AMCMs) were treated with Angiotensin II (AngII) to induce hypertrophy and test EMPA's inhibitory effects.
- Molecular Modeling: Computational docking (Surflex-Dock) was used to predict binding affinities between EMPA and Frizzled receptors (FZD4, FZD5, and FZD8) using structures from the Protein Data Bank (PDB: 5CM4, 5URZ, 1IJY).
- Functional Assays: Luciferase reporter assays (TOPFlash) in HEK293T cells measured Wnt-driven transcriptional activity.
Results
Attenuation of Cardiac Hypertrophy and Fibrosis
EMPA treatment significantly reduced the physical signs of cardiac remodeling in TAC-challenged mice. Treated mice showed lower heart weight to body weight (HW/BW) ratios and reduced cardiomyocyte cross-sectional areas compared to untreated TAC mice. Furthermore, EMPA suppressed the expression of hypertrophic marker genes, including Nppa, Nppb, and Myh7, and significantly decreased cardiac fibrosis.
Improvement of Cardiac Function
Echocardiographic assessment revealed that EMPA preserved heart function over the 8-week study period. While TAC mice typically show a progressive decline in Left Ventricular Ejection Fraction (LVEF) and Fractional Shortening (LVFS), EMPA-treated mice maintained significantly higher functional parameters. Strain analysis via Global Longitudinal Strain (GCS) further confirmed improved myocardial mechanics.
Inhibition of the Wnt/β-catenin Pathway via FZD4
The study identified the Wnt/β-catenin pathway as a primary target for EMPA. Pressure overload normally induces the nuclear translocation of β-catenin, which activates genes driving hypertrophy. EMPA effectively blocked this translocation. Computational docking and cell-based assays suggested that EMPA acts as a molecular brake by binding to the Frizzled-4 (FZD4) receptor, preventing Wnt ligand-induced activation of the downstream cascade.
Discussion
These findings suggest that EMPA provides cardioprotection through a glucose-independent mechanism by directly modulating the Wnt/β-catenin signaling pathway. The identification of FZD4 as a potential direct target for EMPA offers a novel explanation for its success in treating heart failure patients regardless of their diabetic status.
While the results are promising, limitations include the need for further validation of the FZD4 interaction in human tissue and the exploration of other Frizzled receptors. Future research should also investigate the long-term systemic effects of Wnt inhibition and how this pathway interacts with other known effects of SGLT2 inhibitors, such as reduced oxidative stress and inflammation.
Summary updated